Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
Public ClinicalTrials.gov record NCT01473394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
Study identification
- NCT ID
- NCT01473394
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 518 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2011 (Type not available)
- Primary completion
- Feb 2013 (Actual)
- Completion
- Feb 2013 (Actual)
- Last update posted
- Apr 3, 2014
2011 – 2013
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Forest Investigative Site 009 | Beverly Hills | California | 90210 | — |
| Forest Investigative Site 003 | Encino | California | 91316 | — |
| Forest Investigative Site 010 | New Port Beach | California | 92660 | — |
| Forest Investigative Site 005 | Jacksonville | Florida | 32216 | — |
| Forest Investigative Site 004 | Orlando | Florida | 32806 | — |
| Forest Investigative Site 012 | Atlanta | Georgia | 30328 | — |
| Forest Investigative Site 001 | Baltimore | Maryland | 21285 | — |
| Forest Investigative Site 002 | Dayton | Ohio | 45417 | — |
| Forest Investigative Site 011 | Philadelphia | Pennsylvania | 19104 | — |
| Forest Investigative Site 015 | Lincoln | Rhode Island | 02865 | — |
| Forest Investigative Site 008 | Memphis | Tennessee | 38119 | — |
| Forest Investigative Site 016 | San Antonio | Texas | 78229 | — |
| Forest Investigative Site 006 | Bellevue | Washington | 98007 | — |
| Forest Investigative Site 013 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01473394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2014 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01473394 live on ClinicalTrials.gov.